Wall Street Stays Bullish on ImmunityBio Despite Regulatory Headwinds

Despite FDA warning and lawsuits, Wall Street analysts maintain strong buy ratings on ImmunityBio, citing 95% upside potential and robust 700% revenue growth for its cancer drug ANKTIVA.

While a stern FDA warning letter and the threat of shareholder litigation recently erased nearly $2 billion in market capitalization, a surprising consensus has emerged from Wall Street. Rather than triggering a wave of downgrades, the steep sell-off in ImmunityBio shares has solidified analyst confidence, with many seeing substantial upside potential from current levels.

A Striking Disconnect Between Price and Target

The optimism is quantified in a significant gap between the stock's trading price and analyst projections. Following its recent correction, the equity trades around $7. However, the average 12-month price target among covering analysts stands at $14.40. This implies a theoretical upside of over 95%. The consensus recommendation across the seven analysts remains a "Buy" or "Strong Buy." Even the most cautious estimates do not foresee the share price falling below $7, while the most optimistic forecasts reach as high as $23.

Robust Commercial Growth Meets Legal Challenges

This sustained confidence from financial experts is rooted primarily in the company's strong commercial performance. For fiscal year 2025, product revenue surged approximately 700% to $113.3 million. This rapid growth is being driven by the swift market penetration of its bladder cancer therapy, ANKTIVA.

It is this very drug that now sits at the center of regulatory and legal scrutiny. In a warning letter dated March 24, the U.S. Food and Drug Administration accused management of making misleading claims about the drug's efficacy in promotional materials and podcasts. Subsequently, law firms this Sunday publicized renewed class-action lawsuits alleging potential securities violations. These regulatory concerns were the primary catalyst for the stock's recent decline.

International Expansion Continues Unabated

Undeterred by its regulatory issues in the United States, the company continues to advance its global footprint. This week, ImmunityBio secured approval for ANKTIVA in Macau, bringing the total number of countries and territories where the drug is available to over 30.

Looking at the medium-term fundamental picture, the clinical pipeline is coming into focus. An independent committee recently confirmed the robustness of the ongoing QUILT-2.005 study. The firm plans to submit a supplemental approval application for a broader patient population in the fourth quarter of 2026, a move that would significantly expand the addressable market for the cancer treatment.